June 15, 2022
Imagia Canexia Health Achieves First CE-IVD Status in the E.U. to Deploy Comprehensive Cancer Testing Platform
MONTRÉAL, June 15, 2022 – Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe.
June 3, 2022
This article from BioWorld Medtech includes an interview with our CMO David Huntsman, where he discusses Imagia Canexia Health's Candetect project, which is developing precision oncology software that will help monitor resistance to cancer therapy and treatment relapse in individual cancer survivors.
May 19, 2022
Health is becoming digital health, encompassing everything from electronic patient records to telemedicine and mobile health — spurred on by the pandemic. But the next evolution will involve artificial intelligence. While the potential of AI is enormous, there are still a number of challenges to delivering impactful solutions for clinical adoption.
April 21, 2022
Digital Technology Supercluster Announces Investment to Increase the Effectiveness of Precision Oncology
Vancouver, BC [April 21, 2022] – Canada’s Digital Technology Supercluster is excited to be